Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis
暂无分享,去创建一个
David E. Misek | R. Kuick | S. Hanash | T. Giordano | Dafydd G. Thomas | Y. Nikiforov | K. Shedden | M. Vinco | R. Ciampi | Zhaowen Zhu | G. Doherty | R. Koenig | Donita L Sanders | M. Roh | P. Gauger | N. Thompson | Michelle Vinco
[1] M. Nikiforova,et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. , 2005, The Journal of clinical investigation.
[2] J. Mesirov,et al. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis , 2005, Nature Genetics.
[3] S. Wiseman,et al. TIMP1 and SERPIN‐A overexpression and TFF3 and CRABP1 underexpression as biomarkers for papillary thyroid carcinoma , 2004, Head & neck.
[4] D. Sidransky,et al. BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment , 2004, Modern Pathology.
[5] V. Vasko,et al. Chronic expression of RET/PTC 3 enhances basal and insulin‐stimulated PI3 kinase/AKT signaling and increases IRS‐2 expression in FRTL‐5 thyroid cells , 2004, Molecular carcinogenesis.
[6] C. Lohse,et al. Observer Variation in the Diagnosis of Follicular Variant of Papillary Thyroid Carcinoma , 2004, The American journal of surgical pathology.
[7] M. Gariboldi,et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer , 2004, Oncogene.
[8] S. Liyanarachchi,et al. Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] C. Marshall,et al. B-RAF is a therapeutic target in melanoma , 2004, Oncogene.
[10] S. Hanash,et al. Integrated global profiling of cancer , 2004, Nature Reviews Cancer.
[11] F. Zunino,et al. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. , 2004, Journal of the National Cancer Institute.
[12] T. Fahey,et al. 0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(7):3214–3223 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2003-031811 Molecular Profiling Distinguishes Papillary Carcinoma , 2022 .
[13] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[14] H. Holzhausen,et al. The tall-cell variant of papillary thyroid carcinoma: a multivariate analysis of clinical risk factors , 2004, Langenbeck's Archives of Surgery.
[15] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[16] Markus Ringnér,et al. Microarray expression profiling in melanoma reveals a BRAF mutation signature , 2004, Oncogene.
[17] J. Dancey. Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow. , 2004, Cancer cell.
[18] Daniel Birnbaum,et al. Identification and validation of an ERBB2 gene expression signature in breast cancers , 2004, Oncogene.
[19] C. Sawyers. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. , 2003, Genes & development.
[20] M. Nikiforova,et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. , 2003, The Journal of clinical endocrinology and metabolism.
[21] R. Weber,et al. c‐Met expression in tall cell variant papillary carcinoma of the thyroid , 2003, Cancer.
[22] M. Pierotti,et al. The Molecular Basis of Thyroid Epithelial Tumorigenesis , 2003, Tumori.
[23] V. Trovisco,et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC , 2003, Oncogene.
[24] A. Fischer,et al. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. , 2003, American journal of clinical pathology.
[25] P. Ladenson,et al. BRAF mutation in papillary thyroid carcinoma. , 2003, Journal of the National Cancer Institute.
[26] M. Santoro,et al. Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). , 2003, The Journal of clinical endocrinology and metabolism.
[27] I. Shih,et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. , 2003, Journal of the National Cancer Institute.
[28] J. Gray,et al. The genetics and genomics of cancer , 2003, Nature Genetics.
[29] B. Riedl,et al. Design and discovery of small molecules targeting raf-1 kinase. , 2002, Current pharmaceutical design.
[30] Charis Eng,et al. Silencing of the PTEN tumor‐suppressor gene in anaplastic thyroid cancer , 2002, Genes, chromosomes & cancer.
[31] David E. Misek,et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma , 2002, Nature Medicine.
[32] Christos Sotiriou,et al. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. , 2002, Journal of the National Cancer Institute.
[33] J. Fagin. Perspective: Lessons Learned from Molecular Genetic Studies of Thyroid Cancer-Insights into Pathogenesis and Tumor-Specific Therapeutic Targets. , 2002, Endocrinology.
[34] M. Nikiforova,et al. Prevalence of RET/PTC Rearrangements in Hashimoto's Thyroiditis and Papillary Thyroid Carcinomas , 2002, International journal of surgical pathology.
[35] C Eng,et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[36] E. Pravatà,et al. Reply , 2001, British Journal of Cancer.
[37] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[38] G. Bollag,et al. Discovery of a novel Raf kinase inhibitor. , 2001, Endocrine-related cancer.
[39] A. Stoppacciaro,et al. Met protein and hepatocyte growth factor (HGF) in papillary carcinoma of the thyroid: evidence for a pathogenetic role in tumourigenesis , 2001, The Journal of pathology.
[40] E. Dougherty,et al. Gene-expression profiles in hereditary breast cancer. , 2001, The New England journal of medicine.
[41] F. Moretti,et al. Molecular pathogenesis of thyroid nodules and cancer. , 2000, Bailliere's best practice & research. Clinical endocrinology & metabolism.
[42] M. Ringel,et al. Tall Cell Variant: An Aggressive Form of Papillary Thyroid Carcinoma , 2000, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[43] I. Fleming,et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985‐1995 , 1998, Cancer.
[44] A. Bounacer,et al. High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation , 1997, Oncogene.
[45] N. Farid,et al. Immune response to papillary thyroid carcinoma. , 1996, The Journal of clinical endocrinology and metabolism.
[46] S. Asa,et al. Prevalence of activating ras mutations in morphologically characterized thyroid nodules. , 1996, Thyroid : official journal of the American Thyroid Association.
[47] K. Umeki,et al. IMMUNOHISTOCHEMICAL LOSS OF THYROID PEROXIDASE IN PAPILLARY THYROID CARCINOMA: STRONG SUPPRESSION OF PEROXIDASE GENE EXPRESSION , 1996, The Journal of pathology.
[48] A. de Leiva,et al. Ras Oncogene Mutations in Thyroid Tumors: Polymerase Chain Reaction‐Restriction‐Fragment‐Length Polymorphism Analysis from Paraffin‐Embedded Tissues , 1996, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[49] J. Baker. The immune response to papillary thyroid cancer. , 1995, The Journal of clinical endocrinology and metabolism.
[50] T. Oyama,et al. Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas. , 1994, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[51] S. Jhiang,et al. Thyroid peroxidase expression and DNA polymorphisms in thyroid cancer. , 1994, Biochemical and biophysical research communications.
[52] M. Pierotti,et al. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. , 1993, The Journal of clinical investigation.
[53] I D Hay,et al. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. , 1992, The Journal of clinical investigation.
[54] A. Thor,et al. Ras oncogene mutations in benign and malignant thyroid neoplasms. , 1991, The Journal of clinical endocrinology and metabolism.
[55] S. Rubin,et al. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. , 1990, Molecular endocrinology.
[56] E. Kaplan,et al. Natural history, treatment, and course of papillary thyroid carcinoma. , 1990, The Journal of clinical endocrinology and metabolism.
[57] M. Stone. Asymptotics for and against cross-validation , 1977 .